Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus serotype 1 (PV-1) is one of three serotypes of poliovirus responsible for poliomyelitis. It is a non-enveloped virus with a single-stranded, positive-sense RNA genome. PV-1 enters cells via the CD155 receptor and replicates in the oropharynx/gut before potentially invading the central nervous system, leading to paralysis. While wild-type PV-1 is now endemic in only a few countries, vaccine-derived strains can still circulate. Vaccines are available using inactivated or live attenuated virus.
Vaccines induce humoral immunity against the virus, preventing infection and subsequent disease.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus serotype 1.